Derbyshire Medicines Management and Clinical Policies
Home
Medicines Management
Full Traffic Light Classification
Show Drug
Anifrolumab
Size guide:
A
A
A
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Deprescribing
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Inappropriate Requests and Prescribing Concerns in Primary Care
Print this page
Add shortcut to your smart phone
Coronavirus (COVID-19) Treatment
COVID-19 Vaccination Programme
Joint Area Prescribing Committee
JAPC Annual Reports
JAPC Bulletins
JAPC Minutes
JAPC Templates
Full Traffic Light Classification
Traffic Light Classification guidance
Clinical Guidelines
Shared Care Guidelines
Patient Group Directions
Self Care
Deprescribing
Opioid Resources
Out of Area Shared Care Guidelines
Other useful guidelines
Social Care & Care Homes
High Cost Drugs exc. from tariff
Specials
Further Resources
Local & Neighbouring Trust Formularies
Local & Neighbouring Trust Websites
Patient Information
Non UK Patient Information
Controlled Drugs
Contact Us
Anifrolumab
Search the site
Search
Status:
Do Not Prescribe (DNP)
Decision Date:
February 2022
Comments
DNP:
NICE TA793
- Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus (terminated appraisal). (Decision date - July 2022).
search again
Derby and Derbyshire ICB
